Two novel cases of <i>NUTM1</i>‐rearranged B‐cell acute lymphoblastic leukaemia presenting with high‐risk features

McClure, Barbara J.; Pal, Manika; Heatley, Sue L.; Rehn, Jacqueline; Schutz, Caitlin; Breen, James; Venn, Nicola C.; Sutton, Rosemary; Khaw, Seong Lin; Yeung, David T.; White, Deborah L.

doi:10.1111/bjh.17995

Cited by 8 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to NUT carcinoma and infant B‐ALL with KMT2A rearrangements, NUTM1 ‐fusion positive B‐ALL has been linked to a more favorable prognosis. 3 , 5 However, two high‐risk cases of NUTM1 ‐rearranged B‐ALL characterized by early relapse were recently reported, an infant patient with co‐occurring BRD9 :: NUTM1 and P2Y receptor family member 8 ( P2RY8 )::cytokine receptor like factor 2 ( CRLF2 ) fusions and an adult patient with an ACIN1 :: NUTM1 fusion, 14 suggesting that factors affecting prognosis are not fully known.…”

Section: Hematologic Malignancies: Novel Nutm1 ...mentioning

confidence: 99%

The expanding universe of NUTM1 fusions in pediatric cancer

Charlab

Racz

2023

Clinical Translational Sci

View full text Add to dashboard Cite

NUT midline carcinoma family member 1 (NUTM1) fusions were originally identified in poorly differentiated and clinically aggressive carcinomas typically located in the midline structures of children and young adults, and collectively known as NUT (midline) carcinomas. Next‐generation sequencing later uncovered NUTM1 fusions in a variety of other pediatric and adult cancers of diverse location and type, including hematologic malignancies, cutaneous adnexal tumors, and sarcomas. A vast array of NUTM1 fusions with bromodomain containing 4 (BRD4) or bromodomain containing 3 (BRD3), which are characteristic of NUT carcinoma, and with several other fusion partners have been identified and associated with variable prognosis. These non‐kinase fusions are thought to cause epigenetic reprogramming, thereby promoting proliferation, and hindering the differentiation of cancer cells. Many questions about both the function of the naïve NUTM1 protein, which is mostly restricted to the germ cells of the testis and is related to spermatogenesis and the oncogenic mechanisms of the various NUTM1 fusions in both adult and pediatric cancer, are still unanswered. Moreover, whether there is a relationship defined by the presence of NUTM1 fusions between conventional NUT carcinoma and other NUTM1‐rearranged neoplasms remains to be elucidated. This review will focus on recent discoveries of NUTM1 fusions found in pediatric cancers, their prognostic impact, and emergence as novel oncogenic drivers.

show abstract

Section: Hematologic Malignancies: Novel Nutm1 ...mentioning

confidence: 99%